Seladelpar, branded as Lyvdelzi▼, has received conditional approval from the European Commission for treating primary biliary cholangitis (PBC). It is indicated for adults with inadequate response to UDCA or those unable to tolerate it.
The drug, a selective PPAR Delta agonist, shows promise in stabilizing liver stiffness and improving symptoms. Developed by Gilead Sciences, it targets patients needing second-line therapy.
Professor David Jones of Newcastle University highlights its role in evolving PBC management - emphasizing earlier diagnosis, risk stratification, and treatment goals.
▼This medicinal product is under additional monitoring to rapidly identify new safety data.